TransCode Therapeutics, Inc. (RNAZ) NASDAQ
8.55
+0.19(+2.27%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
8.55
+0.19(+2.27%)
Currency In USD
| Previous Close | 8.36 |
| Open | 8.43 |
| Day High | 8.57 |
| Day Low | 8.22 |
| 52-Week High | 22.04 |
| 52-Week Low | 6.08 |
| Volume | 2,829 |
| Average Volume | 215,701 |
| Market Cap | 7.84M |
| PE | -0.04 |
| EPS | -236.52 |
| Moving Average 50 Days | 9.59 |
| Moving Average 200 Days | 9.89 |
| Change | 0.19 |
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
GlobeNewswire Inc.
Nov 29, 2024 9:25 PM GMT
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
GlobeNewswire Inc.
Nov 27, 2024 12:00 PM GMT
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a securities purchase ag
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
GlobeNewswire Inc.
Nov 25, 2024 12:00 PM GMT
Split designed to achieve compliance with Nasdaq minimum bid price requirementsBOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effecti